Dr. Tzachanis on the Likelihood of Cure With CAR T-Cell Therapy in Lymphoma

Video

Dimitrios Tzachanis, MD, PhD, discusses the likelihood of cure with CAR-T cell therapy in lymphoma.

Dimitrios Tzachanis, MD, PhD, hematologist/medical oncologist and assistant professor of medicine, University of California, San Diego Health, discusses the likelihood of cure with CAR-T cell therapy in lymphoma.

According to Tzachanis, it is difficult to definitively say that a patient is cured from their cancer.

However, since diffuse large B-cell lymphoma and acute lymphoblastic leukemia are fast-growing diseases, patients who derive at least 2-year remissions with CAR T-cell therapy may be effectively cured, concludes Tzachanis.

Recent Videos
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Brian Kim, MBA, the chief executive officer of Mission Bio
Peter Cook, PhD, a senior research scientist at Seattle Children’s Research Institute
Nicholas Giovannone, PhD, a senior principal scientist at Regeneron
Related Content
© 2025 MJH Life Sciences

All rights reserved.